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accounting for characteristic alternating rings of hypo- 
and hyperintensity on T2-weighted images [9,10]. 
The large number of cerebral lesions results from 
widespread hernatogenous dissemination, as attested by 
the frequency of extracranial involvement: the lung is 
most often involved [6], but other tissues may be con- 
cerned, e.g. liver, bone, skin and epididymis. However, 
associated meningitis is far from frequent [ l l ] .  Extra- 
cranial localizations usually provide bacteriologic and/ 
or histologic coilfirmation of diagnosis, when, as in this 
case, the pathogen is not isolated from the CSE 
Given antituberculous therapy, patients usually make 
a good recovery within a few months [3,7]. As in cases 
of single tuberculoma, adjunctive therapy with steroids 
rapidly improves neurologic symptoms in patients 
with marked brain edema [6]. In our patient, clinical 
recovery was obtained after 8 months, but persistence 
of M R  abnormalities led to a prolonged treatment. 
This evolution is not unusual. Indeed, while extra- 
neurologic manifestations and most intracranial lesions 
regress, some of them, particularly the large ones, 
can persist or enlarge [3]. In most cases, however, a 
prolonged course of antibiotic therapy for a continuous 
total period of 18 or 24 months is successful [12,13]. 
In conclusion, this case demonstrates a particular 
type of cerebral tuberculous involvement, very different 
from classic single tuberculoma. Multiple intracranial 
tuberculomas are paradoxically associated with few 
neurologic signs. The search for the frequently associated 
extracranial involvement is an important step in diag- 
nosis; this can be strongly suggested by CT and M R  
findings. The slow improvement in clinical and especially 
radiologic abnormalities with antituberculous therapy 
suggests that a prolonged treatment course and routine 
neuroimaging follow-up may be necessary. 
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Reduced susceptibility to quinolones in Salmonella typhi 
acquired in Europe: a clinical failure of treatment 
Clin Microbiol Infect 1997; 3: 576-577 
Multidrug-resistant Salmonella typhi is becoming a 
problem in developing and in developed countries. 
Third-generation cephalosporins and fluoroquinolones 
have become the treatment of choice. Fluoroquino- 
lones reduce the duration of fever, the duration of 
treatment and the prevalence of chronic intestinal 
carriage, and they can be administered orally. Among 
fluoroquinolones, ciprofloxacin is the most active: 
the ranges from 0.007 to 0.012 pg/mL [1,2] or 
0.015 pg/mL according to other authors [3]. Quino- 
lone-resistant S. typhi strains were first described in 
1988 in India [4,5]. All cases reported from European 
countries have concerned patients infected in Asia [6]. 
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European reports of quinolone resistance involve mostly 
Salmonella strains other than S. typhi [7,8]. 
We report a clinical failure of fluoroquinolone 
treatment, in a 45-year-old Portuguese man living in 
France, occurring 14 days after a journey in the north 
of Portugal (Braganca). The patient was admitted in 
October 1994 and gave no history of past travel outside 
Europe or recent antimicrobial treatment, particularly 
with any quinolone. Three blood cultures on admission 
were positive for S. typhi. Intravenous treatment with 
pefloxacin (800 mg/day) for 72 h, followed by 48 h of 
oral treatment with ciprofloxacin (1 g/day), had no 
effect on the patient’s fever, general condition or 
gastrointestinal signs. A blood culture was still positive 
after 48 h of pefloxacin treatment. O n  the sixth day of 
hospitalization, the appearance of hypothermia resulted 
in reassessment and modification of the treatment to 
intravenous amoxicillin (6 g/day). His temperature 
became normal within 24 h and blood culture became 
negative. Stool cultures 1 month later were negative. 
The isolates of S. typhi were lysotype A, as deter- 
mined by the French Reference Center for Salmonella 
and Shigella, Institut Pasteur, Paris. Susceptibilities were 
determined by a tube dilution method, in Mueller- 
Hinton broth with an inoculum of lo6 CFU/mL and 
incubation at  37OC for 24 h; Escherichia coli 25922 
was used as control. Those isolates were susceptible 
to ampicillin (MIC 1 pg/mL), piperacillin, cefalothin, 
cefotaxime and chloraniphenicol, but showed reduced 
susceptibility to ciprofloxacin (MIC 0.12 pg/niL) and 
pefloxacin (MIC 1 pg/mL). 
The failure of fluoroquinolone treatment has already 
been described by Umasankar et a1 [9]. A child was 
treated with ciprofloxacin orally at 20 mg/kg/day for 
10 days with no clinical improvement. The reported 
strain showed reduced susceptibility to ciprofloxacin 
(MIC 0.5 pg/mL) and resistance to nalidixic acid (MIC 
>128 pg/mL). Recent reports [10,11] suggest that in 
infection by inultiresistant strains of S. typhi which 
remain fully sensitive to fluoroquinolones, short courses 
of fluoroquinolones (of 2-5 days) are clinically effective. 
In our case, the low-grade fluoroquinolone resistance 
led to clinical failure after 5 days of fluoroquinolone 
treatment. Clinicians and microbiologists should be 
aware that this degree of reduction in susceptibility, 
which may not be demonstrated by disk testing 
with ciprofloxacin, contraindicates the use of fluoro- 
quinolones in treatment. Alternative antibiotics, such as 
chloramphenicol, amoxicillin or a third-generation 
cephalosporin, should be used. 
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Endocarditis caused by Enterococcus faecalis with high- 
level resistance to aminoglycosides: failure of ampicillin 
and ceftriaxone combined therapy 
Clin Microbiol I tz fc t  1997; 3: 577-580 
Enterococci account for 10-15%, of cases of endo- 
carditis [1,2]. Since these organisms are tolerant to cell 
wall active agents (penicillins and glycopeptides), an  
aminoglycoside must be added to these antibiotics to 
obtain synergistic bactericidal activity 11,2]. Unfor- 
tunately, enterococci with high-level resistance (HLK) 
to gentamicin and streptomycin have emerged in many 
countries in recent years, and this may create a serious 
